Information

Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Directly acting antivirals against hepatitis C virus.

Title :
Directly acting antivirals against hepatitis C virus.
Authors :
Soriano V; Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain. />Vispo E
Poveda E
Labarga P
Martin-Carbonero L
Fernandez-Montero JV
Barreiro P
Show more
Source :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2011 Aug; Vol. 66 (8), pp. 1673-86. Date of Electronic Publication: 2011 Jun 07.
Publication Type :
Journal Article; Research Support, Non-U.S. Gov't; Review
Language :
English
Imprint Name(s) :
Publication: 1997- : London : Oxford University Press
Original Publication: London, New York, Academic Press.
MeSH Terms :
Antiviral Agents/*therapeutic use
Hepacivirus/*drug effects
Hepatitis C, Chronic/*drug therapy
Hepatitis C, Chronic/*virology
Antiviral Agents/pharmacology ; Clinical Trials as Topic ; Drug Approval ; Drug Discovery/trends ; Hepatitis C, Chronic/epidemiology ; Humans ; Oligopeptides/pharmacology ; Oligopeptides/therapeutic use ; Proline/analogs & derivatives ; Proline/pharmacology ; Proline/therapeutic use
Substance Nomenclature :
0 (Antiviral Agents)
0 (Oligopeptides)
655M5O3W0U (telaprevir)
89BT58KELH (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
9DLQ4CIU6V (Proline)
Entry Date(s) :
Date Created: 20110610 Date Completed: 20111031 Latest Revision: 20141120
Update Code :
20210210
DOI :
10.1093/jac/dkr215
PMID :
21652618
Academic Journal
The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic viral disease that can be cured, as all other pathogenic viruses infecting humans either display self-limited courses or establish non-eradicable persistent infections. Until now, treatment of chronic hepatitis C consisted of the combination of peginterferon-α plus ribavirin, which provided limited rates of cure and was associated with frequent side effects. Several DAA have been identified that inhibit the NS3 protease, the NS5B polymerase or the NS5A replication complex, and have entered the final steps of clinical development. These molecules, coupled with significant progress made in the recognition of more potent and safe interferon forms (e.g. interferon-λ) and host protein targets (e.g. alisporivir), are opening a new era in hepatitis C therapeutics. The expectations are so great that, to some extent, it is reminiscent of what happened in 1996 in the HIV field when the introduction of the first protease inhibitors as part of triple combinations revolutionized antiretroviral therapy. To maximize treatment success and reduce the likelihood of drug resistance selection, a proper individualization of hepatitis C therapy will be required, choosing the most convenient drugs and strategies according to distinct viral and host profiles. The complexity of HCV therapeutics has reached a point that presumably will lead to the birth of a new specialist, the HCV doctor.

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.